At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Parsaclisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
In Brief
A Phase 2 clinical trial evaluating Parsaclisib for Autoimmune Hemolytic Anemia. Completed, enrolled 25 participants across 12 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of parsaclisib administered orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin and evidence of ongoing hemolysis that requires treatment intervention.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutoimmune Hemolytic Anemia
CountriesAustria, France, Italy, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartNov 2018
Primary CompletionAug 2021
Study CompletionApr 2024
TodayJul 2026
First PostedMay 25, 2018
Enrollment StartNov 21, 2018
Primary CompletionAug 5, 2021
Study CompletionApr 2, 2024
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.1 years ago
Interventions
Parsaclisibdrug
Parsaclisib administered orally.